Propanc Biopharma Inc (OTCMKTS:PPCB) revealed Monday that it is on the cusp of producing synthetic versions of the two pancreatic proenzymes – trypsinogen and chymostrypsinogen – which make up its lead product, the cancer-fighting drug PRP.
“We are pleased with the recent advancements made through our research program, as we are able to produce synthetic recombinant versions of the two proenzymes, trypsinogen and chymostrypsinogen,” said Dr. Julian Kenyon, Propanc’s chief scientific officer. “The two active ingredients are currently naturally derived from animal sources, which combine to form our lead product candidate, PRP.”
The “significant advances” made by Propanc’s POP1 research program – which is being conducted with scientists at the Universities of Jaén and Granada in Spain – bring the Australian company closer to producing large quantities of trypsinogen and chymostrypsinogen for commercial use.
“As we seek to expand our product pipeline, our vision is to create a new drug product class that provides a solution for the treatment and prevention of recurring and spreading malignant tumors, once perceived as untreatable,” added James Nathanielsz, Propanc’s CEO.
A key goal of the POP1 project – now being carried out in research labs at Jaén and Granada – is to synthesize this critical pair of pancreatic proenzymes to produce crystalized proteins that can be kept for lengthy periods without refrigeration. Figuring out a way to do this is crucial to the extension of PRP’s shelf life as well as its distribution internationally, especially in warmer areas and developing countries.
PRP works by suppressing cellular pathways involved in the Epithelial to Mesenchymal transition, a process which causes metastasis in cancer stem cells and which can trigger secondary tumors.
Propanc’s central scientific thesis is that enzymes secreted by the pancreas stimulate biological reactions in the body and can act as a defense against cancer.
The Australian company says the pancreatic proenzymes target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.
In early afternoon trade, Propanc shares slipped 5.5% to hover at US$0.34 in over-the-counter trading.
Contact Ellen at [email protected]